Related Experiment Video

Updated: May 10, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

The role of β-arrestins in cancer

Philip Michael Sobolesky1, Omar Moussa

  • 1Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.

Progress in Molecular Biology and Translational Science
|June 15, 2013
PubMed

Insights

Beta-arrestins (ARRBs) regulate key cancer cell functions like proliferation and migration. Their dysregulation is linked to aggressive cancers, suggesting ARRBs as potential therapeutic targets.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Cellular Signaling

Background:

  • Beta-arrestins (ARRBs) are known regulators of G protein-coupled receptor signaling.
  • Emerging evidence implicates ARRBs in fundamental cellular processes beyond receptor trafficking, including cell cycle, migration, and apoptosis.
  • The role of ARRBs in cancer is increasingly recognized, with significant implications for disease progression.

Purpose of the Study:

  • To review and synthesize the evidence for beta-arrestin involvement in cancer.
  • To highlight the mechanisms by which ARRBs influence cancer phenotypes.
  • To explore the therapeutic potential of targeting ARRB-dependent pathways in malignancies.

Main Methods:

  • Review of in vitro studies on ARRB function in cancer cells.
  • Analysis of data from animal models of cancer.
  • Examination of clinical studies correlating ARRB status with patient outcomes.

Main Results:

  • In vitro, ARRBs promote proliferation, migration, and survival by scaffolding signaling networks and regulating gene expression.
  • In vivo, ARRB expression impacts tumor initiation, growth, vascularization, hypoxia survival, invasiveness, and metastasis.
  • Clinical studies show ARRB dysregulation correlates with aggressive cancer phenotypes and poor outcomes in various malignancies.

Conclusions:

  • Beta-arrestin-mediated signaling significantly contributes to the cancer phenotype.
  • ARRBs represent promising novel therapeutic targets for specific cancer types.
  • Further research into ARRB-dependent pathways could unveil new treatment strategies.

More Related Videos

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.